

**Author(s):** Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

**Question:** Should Monoclonal antibodies REGN-CoV2 any dosages compared to Placebo be used for COVID-19 patients?

**Setting:** Outpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Monoclonal antibodies REGN-CoV2	Placebo	Relative (95% CI)	Absolute (95% CI)	

**All-cause mortality (2.4g)**

1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	serious <sup>b</sup>	none	No deaths reported				⊕⊕○○ LOW
----------------	-------------------	----------------------	-------------	-------------	----------------------	------	--------------------	--	--	--	-------------

**Number of patients with any adverse event (2.4g)**

1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>c</sup>	none	0/88 (0.0%)	2/93 (2.2%)	<b>RR 0.21</b> (0.01 to 4.34)	<b>17 fewer per 1.000</b> (from 21 fewer to 72 more)	⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	-------------	-------------	----------------------------------	---	------------------

**Number of patients with serious adverse events (2.4g)**

1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>c</sup>	none	1/88 (1.1%)	2/93 (2.2%)	<b>RR 0.53</b> (0.05 to 5.72)	<b>10 fewer per 1.000</b> (from 20 fewer to 102 more)	⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	-------------	-------------	----------------------------------	--	------------------

**All-cause mortality (8g)**

1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	serious <sup>b</sup>	none	No deaths reported				⊕⊕○○ LOW
----------------	-------------------	----------------------	-------------	-------------	----------------------	------	--------------------	--	--	--	-------------

**Number of patients with any adverse event (8g)**

1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>c</sup>	none	2/88 (2.3%)	2/93 (2.2%)	<b>RR 1.06</b> (0.15 to 7.34)	<b>1 more per 1.000</b> (from 18 fewer to 136 more)	⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	-------------	-------------	----------------------------------	--	------------------

**Number of patients with serious adverse events (8g)**

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Monoclonal antibodies REGN-CoV2	Placebo	Relative (95% CI)	Absolute (95% CI)	
1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>c</sup>	none	0/88 (0.0%)	2/93 (2.2%)	<b>RR 0.21</b> (0.01 to 4.34)	<b>17 fewer per 1.000</b> (from 21 fewer to 72 more)	⊕○○○ VERY LOW

#### Explanations

- a. Downgraded of one level for high risk of reporting bias and unclear risk of selection bias
- b. Downgraded of one level for small sample size (<200)
- c. Downgraded of two levels for small sample size and wide CI

#### References

1. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.